Coca-Cola's stock is suffering its worst day in 17 months as concerns over consumer spending grows
Shares of Coca-Cola Co. (KO) were suffering their worst day in 17 months Thursday, amid a broad selloff in their consumer-staples peers and the broader stock market, amid growing fears that high interest rates and a slowing job market will derail the U.S. economy. The beverage giant's stock slumped 4.1% in afternoon trading, enough to lead the Dow Jones Industrial Average's losers. That would be the biggest one-day decline since it dropped 7.0% on May 18, 2022. The stock was also headed for its lowest close since Dec. 1, 2021. The Consumer Staples Select Sector SPDR ETF (XLP) was down 1.5% toward a one-year low and the S&P 500 gave up 0.2%. Earlier Thursday, branded consumer foods company Conagra Brands Inc. (CAG), which is also a component of the consumer staples ETF, reported quarterly sales that fell short of expectations, amid an "industry-wide slowdown in consumption and recent consumer behavior shifts."
-Tomi Kilgore
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
10-05-23 1355ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks